Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease

International Journal of Molecular Medicine

Volumn 32, Issue 4, 2013, Pages 883-891

  Zhao, Qing ^a   Cai, Dingfang ^b,c   Bai, Yu ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Institute of Radiation Medicine   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Gait analysis; Glial cell line derived neurotrophic factor; Neurorescue; Parkinson's disease; Selegiline

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NEUROTROPHIC FACTOR; PROTEIN BAX; PROTEIN BCL 2; SELEGILINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GAIT DISORDER; HINDLIMB; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GAIT; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELEGILINE;

EID: 84883389528     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1450     Document Type: Article

References (49)

1. Lees AJ, Hardy J and Revesz T: Parkinson's disease. Lancet 373: 2055-2066, 2009.
2. Stocchi F, Vacca L, Grassini P, et al: Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67: S24-S29, 2006.
3. Bar-Am O, Weinreb O, Amit T and Youdim MB: The neuroprotective mechanism of 1?(R)?aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 112: 1131-1137, 2010.
4. Olanow CW, Hauser RA, Jankovic J, et al: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23: 2194-2201, 2008.
5. Weinreb O, Mandel S, Bar-Am O, et al: Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 6: 163-174, 2009.
6. Chen JJ and Ly AV: Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 63: 915-928, 2006.
7. Magyar K, Pálfi M, Jenei V and Szöko E: Deprenyl: from chemical synthesis to neuroprotection. J Neural Transm Suppl 143-156, 2006.
8. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S and Youdim MB: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 457-465, 2006.
9. Youdim MB, Maruyama W and Naoi M: Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41: 369-391, 2005.
10. Youdim MB and Tipton KF: Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord 8: 247-253, 2002.
11. Hara MR, Thomas B, Cascio MB, et al: Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 103: 3887-3889, 2006.
12. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB and Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24: 675-682, 2002.
13. Maruyama W, Nitta A, Shamoto-Nagai M, et al: N-Propargyl?1 (R)?aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44: 393-400, 2004.
14. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O and Youdim MB: Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl?2 family members. FASEB J 18: 1471-1473, 2004.
15. Sagi Y, Mandel S, Amit T and Youdim MB: Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25: 35-44, 2007.
16. Zhu W, Xie W, Pan T, et al: Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105: 1970-1978, 2008.
17. Jackson-Lewis V and Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151, 2007.
18. Perier C, Bové J, Wu DC, et al: Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci USA 104: 8161-8166, 2007.
19. Fernagut PO, Diguet E, Labattu B and Tison F: A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113: 123-130, 2002.
20. Fleming SM, Salcedo J, Fernagut PO, et al: Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24: 9434-9440, 2004.
21. Tillerson JL, Caudle WM, Reverón ME and Miller GW: Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl?4-phenyl?1,2,3,6-tetrahydropyridine. Exp Neurol 178: 80-90, 2002.
22. Paxinos G and Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 4th edition. Elsevier Academic Press, San Diego, 2012.
23. He XJ, Yamauchi H, Uetsuka K and Nakayama H: Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease. Neurotoxicology 29: 413-420, 2008.
24. Yokoyama H, Takagi S, Watanabe Y, Kato H and Araki T: Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm 115: 831-842, 2008.
25. Kuhn K, Wellen J, Link N, Maskri L, Lübbert H and Stichel CC: The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci 17: 1-12, 2003.
26. West MJ and Gundersen HJ: Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296: 1-22, 1990.
27. Wu DC, Jackson-Lewis V, Vila M, et al: Blockade of microglial activation is neuroprotective in the 1-methyl?4-phenyl?1,2, 3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771, 2002.
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method. methods 25: 402-408, 2001.
29. Matsunaga W, Isobe K and Shirokawa T: Involvement of neurotrophic factors in aging of noradrenergic innervations in hippocampus and frontal cortex. Neurosci Res 54: 313-318, 2006.
30. Novikova L, Garris BL, Garris DR and Lau YS: Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl?4-phenyl?1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience 140: 67-76, 2006.
31. Blin O, Ferrandez AM and Serratrice G: Quantitative analysis of gait in Parkinson patients: increased variability of stride length. J Neurol Sci 98: 91-97, 1990.
32. Muller T: Drug therapy in patients with Parkinson's disease. Transl Neurodegener 1: 10, 2012.
33. Lewitt PA: MAO-B inhibitor know-how: back to the pharm. Neurology 72: 1352-1357, 2009.
34. Parkinson Study Group: DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46: 1052-1060, 1989.
35. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59: 1937-1943, 2002.
36. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F and Tolosa E; ADAGIO Study Investigators: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278, 2009.
37. Ansari KS, Yu PH, Kruck TP and Tatton WG: Rescue of axotomized immature rat facial motoneurons by R(?)?deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042-4053, 1993.
38. Sharma SK, Carlson EC and Ebadi M: Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)?induced apoptosis in SK-N-SH neurons. J Neurocytol 32: 329-343, 2003.
39. Tatton WG, Chalmers-Redman RM, Ju WJ, et al: Propargylamines induce antiapoptotic new protein synthesis in serum? and nerve growth factor (NGF)?withdrawn, NGF-differentiated PC?12 cells. J Pharmacol Exp Ther 301: 753-764, 2002.
40. Holschneider DP, Chen K, Seif I and Shih JC: Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull 56: 453-462, 2001.
41. Weinreb O, Amit T, Bar-Am O and Youdim MB: Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann NY Acad Sci 1122: 155-168, 2007.
42. Ebadi M, Sharma S, Shavali S and El Refaey H: Neuroprotective actions of selegiline. J Neurosci Res 67: 285-289, 2002.
43. Levy OA, Malagelada C and Greene LA: Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14: 478-500, 2009.
44. Tanaka K, Asanuma M and Ogawa N: Molecular basis of anti-apoptotic effect of immunophilin ligands on hydrogen peroxide-induced apoptosis in human glioma cells. Neurochem Res 29: 1529-1536, 2004.
45. Meredith GE and Kang UJ: Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 21: 1595-1606, 2006.
46. Patel M, Mao L, Wu B and Vandevord PJ: GDNF-chitosan blended nerve guides: a functional study. J Tissue Eng Regen Med 1: 360-367, 2007.
47. Piquilloud G, Christen T, Pfister LA, Gander B and Papaloïzos MY: Variations in glial cell line-derived neurotrophic factor release from biodegradable nerve conduits modify the rate of functional motor recovery after rat primary nerve repairs. Eur J Neurosci 26: 1109-1117, 2007.
48. Willson ML, McElnea C, Mariani J, Lohof AM and Sherrard RM: BDNF increases homotypic olivocerebellar reinnervation and associated fine motor and cognitive skill. Brain 131: 1099-1112, 2008.
49. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R and Young B: Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222, 2005.